36 Finally, a cross-sectional study also demonstrated adverse effects of GLP-1 agonists, with patients on exenatide reporting higher PHQ-9 scores (9.70 4.92 vs 6.70 4.66
Triple agonist or GIP/GLP-1/glucagon receptor agonist is more accurate because the compound does not act on a receptor called GLP-3
Mean percent changes from baseline at Week 24 were 0.0% versus 2.5% for total cholesterol, and -1.0% versus 2.9% for LDL cholesterol in the placebo and dapagliflozin 10 mg groups, respectively
70,71 Additionally, the exploration of GLP-1R positive allosteric modulators (PAMs) offers a new regulatory approach that could enhance the therapeutic profile of small-molecule GLP-1R agonists
Almandoz JP, Wadden TA, Tewksbury C, et al
A trial published in The New England Journal of Medicine (2023) demonstrated mean weight reductions of up to approximately 24% of body weight over 48 weeks in adults with obesity a potentially significant finding if confirmed in Phase 3 trials